As flu vaccination continues for the 2026–2027 respiratory virus season, online conversations are highlighting questions about vaccine eligibility, safety, effectiveness, and access. Some social media users are repeating false claims about flu vaccine ingredients, including claims that the vaccines contain unsafe levels of mercury or can cause serious health problems.
Meanwhile, the availability of mFlusiva, a new mRNA flu vaccine approved for adults ages 50 and older, has generated continued questions and concerns. Some social media users repeated false claims about mRNA vaccine safety, including that the vaccines alter DNA or cause cancer. Others questioned the benefits of the new vaccine compared with traditional flu vaccines, expressed uncertainty about age eligibility and potential side effects, or reported difficulty finding their preferred vaccine at local pharmacies.
Recommendation
Health communicators can address safety concerns and confusion about flu vaccine options by explaining which vaccines are available for different age groups, how they work, and what is known about their safety and effectiveness. Messaging should clarify eligibility, potential side effects, and where people can find available vaccines, while emphasizing that annual flu vaccination reduces the risk of severe illness and hospitalization.
Reading links: Infodemiology Initiative
Communication resources: Get tips for communicating about flu vaccines in 2026-2027
